Literature DB >> 26578231

Impact of Genetic Counseling and Testing on Altruistic Motivations to Test for BRCA1/2: a Longitudinal Study.

Rahul Garg1, Joseph Vogelgesang2, Kimberly Kelly3,4.   

Abstract

Despite the importance of altruism in an individual's participation in genetic counseling and testing, little research has explored the change in altruistic motivations to test over time. This study analyzed altruistic motivations to test and change in altruistic motivations after genetic counseling and testing among individuals (N = 120) at elevated risk for BRCA1/2 mutations. The perceived benefits of genetic testing were assessed and utilized in a mixed-methods, repeated measures design at three time points: pre-counseling, counseling and post-genetic testing, along with transcripts of genetic counseling sessions. Qualitative analysis using an immersion/crystallization method resulted in six common perceived benefits of testing: cancer prevention, awareness, family's survival, relief from anxiety, for science, and future planning. Perceived benefits were then coded into three categories according to Hamilton's kin selection theory: altruistic motivation, personal motivation, and motivation for mutual benefit. At pre-counseling, those with a personal cancer history (p = 0.003) and those with one or more children (p = 0.013), were significantly more likely to cite altruistic motivations to test. Altruistic motivations significantly increased post-counseling (p = 0.01) but declined post-testing (p < 0.001). Labov's narrative analysis further elucidated the context of altruistic and personal motivations. The possibility of a positive test result might have led those with personal history of cancer to have altruistic motivations for testing. Genetic counseling may have increased altruistic motivations to help family and may be a prime opportunity to discuss other forms of altruism.

Entities:  

Keywords:  Altruism; BRCA1/2; Genetic counseling; Genetic testing; Motivation to test

Mesh:

Year:  2015        PMID: 26578231      PMCID: PMC4870135          DOI: 10.1007/s10897-015-9911-z

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  29 in total

1.  Motivations and psychosocial impact of genetic testing for HNPCC.

Authors:  M J Esplen; L Madlensky; K Butler; W McKinnon; B Bapat; J Wong; M Aronson; S Gallinger
Journal:  Am J Med Genet       Date:  2001-09-15

2.  Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer.

Authors:  Claudine Isaacs; Beth N Peshkin; Marc Schwartz; Tiffani A Demarco; David Main; Caryn Lerman
Journal:  Breast Cancer Res Treat       Date:  2002-01       Impact factor: 4.872

3.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.

Authors:  S K McDonnell; D J Schaid; J L Myers; C S Grant; J H Donohue; J E Woods; M H Frost; J L Johnson; D L Sitta; J M Slezak; T B Crotty; R B Jenkins; T A Sellers; L C Hartmann
Journal:  J Clin Oncol       Date:  2001-10-01       Impact factor: 44.544

4.  Genetic counseling content: How does it impact health behavior?

Authors:  Kimberly M Kelly; Lee Ellington; Nancy Schoenberg; Thomas Jackson; Stephanie Dickinson; Kyle Porter; Howard Leventhal; Michael Andrykowski
Journal:  J Behav Med       Date:  2014-12-23

5.  Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

Authors:  David M Euhus; Kristin C Smith; Linda Robinson; Amy Stucky; Olufunmilayo I Olopade; Shelly Cummings; Judy E Garber; Anu Chittenden; Gordon B Mills; Paula Rieger; Laura Esserman; Beth Crawford; Kevin S Hughes; Connie A Roche; Patricia A Ganz; Joyce Seldon; Carol J Fabian; Jennifer Klemp; Gail Tomlinson
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

6.  Genetic testing for hereditary breast and ovarian cancer: responsibility and choice.

Authors:  Lori d'Agincourt-Canning
Journal:  Qual Health Res       Date:  2006-01

7.  BRCA mutations and risk of prostate cancer in Ashkenazi Jews.

Authors:  Tomas Kirchhoff; Noah D Kauff; Nandita Mitra; Kedoudja Nafa; Helen Huang; Crystal Palmer; Tony Gulati; Eve Wadsworth; Sheri Donat; Mark E Robson; Nathan A Ellis; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

8.  Motivations and concerns of women considering genetic testing for breast cancer: a comparison between affected and at-risk probands.

Authors:  Rachael Brandt; Ellen Hartmann; Zonera Ali; Rosemarie Tucci; Paul Gilman
Journal:  Genet Test       Date:  2002

9.  Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease.

Authors:  J Scott Roberts; Susan A LaRusse; Heather Katzen; Peter J Whitehouse; Melissa Barber; Stephen G Post; Norman Relkin; Kimberly Quaid; Robert H Pietrzak; L Adrienne Cupples; Lindsay A Farrer; Tamsen Brown; Robert C Green
Journal:  Alzheimer Dis Assoc Disord       Date:  2003 Apr-Jun       Impact factor: 2.703

10.  A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.

Authors:  Lisa Soleymani Lehmann; Jane C Weeks; Neil Klar; Judy E Garber
Journal:  Genet Med       Date:  2002 Sep-Oct       Impact factor: 8.822

View more
  4 in total

1.  Influences of race and breast density on related cognitive and emotion outcomes before mandated breast density notification.

Authors:  Mark Manning; Terrance L Albrecht; Zeynep Yilmaz-Saab; Julie Shultz; Kristen Purrington
Journal:  Soc Sci Med       Date:  2016-10-10       Impact factor: 4.634

2.  Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations.

Authors:  Ishveen Chopra; Kimberly M Kelly
Journal:  J Health Commun       Date:  2017-01-23

3.  How do providers discuss the results of pediatric exome sequencing with families?

Authors:  Sarah A Walser; Allison Werner-Lin; Rebecca Mueller; Victoria A Miller; Sawona Biswas; Barbara A Bernhardt
Journal:  Per Med       Date:  2017-09-04       Impact factor: 2.512

4.  Patient and Provider Perspectives on Enrollment in Precision Oncology Research: Qualitative Ethical Analysis.

Authors:  Andrew G Shuman; Kayte Spector-Bagdady; Madison Kent; Chris D Krenz; Collin Brummel; Paul L Swiecicki; J Chad Brenner
Journal:  JMIR Cancer       Date:  2022-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.